Literature DB >> 8863670

Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors.

K Scotlandi1, N Baldini, M Oliviero, M F Di Renzo, M Martano, M Serra, M C Manara, P M Comoglio, R Ferracini.   

Abstract

Overexpression of the hepatocyte growth factor receptor (Met/HGF receptor), a transmembrane tyrosine kinase encoded by the met proto-oncogene, has been associated with tumor progression in different human carcinomas. More recently, the Met/HGF receptor has also been described in tumor cell lines of mesenchymal origin, suggesting the existence of an autocrine loop that may contribute to the pathogenesis of sarcomas. In this study, we analyzed the expression of Met/HGF receptor by Western blotting and immunohistochemistry in frozen samples of 87 primary tumors of bone and soft tissues. Among benign tumors, overexpression was consistently found only in giant-cell tumor, a locally aggressive lesion that may also, although rarely, spread to the lung. Among malignant lesions, the presence of the Met/HGF receptor was detected in a relevant percentage of primaries and in almost all of the recurrences. The highest levels of Met/HGF receptor were found in osteosarcoma, a highly aggressive tumor that typically permeates the host bone and rapidly expands to the soft tissues. On the contrary, only low levels of Met/HGF receptor were found in chondrosarcoma, a slowly growing tumor that usually expands without massive destruction of the surrounding structures. These data indicate an association of Met/HGF expression with local aggressiveness in human mesenchymal tumors. The finding of Met/HGF receptor overexpression in all of the osteosarcomas suggests a role for the met proto-oncogene in the pathogenesis of this tumor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8863670      PMCID: PMC1865197     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  47 in total

Review 1.  Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product.

Authors:  J S Rubin; D P Bottaro; S A Aaronson
Journal:  Biochim Biophys Acta       Date:  1993-12-23

2.  Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation.

Authors:  S Rong; S Segal; M Anver; J H Resau; G F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

3.  Met expression and sarcoma tumorigenicity.

Authors:  S Rong; M Jeffers; J H Resau; I Tsarfaty; M Oskarsson; G F Vande Woude
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

4.  Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network.

Authors:  M Jeffers; S Rong; G F Vande Woude
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

5.  Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients.

Authors:  S Rong; L A Donehower; M F Hansen; L Strong; M Tainsky; M Jeffers; J H Resau; E Hudson; I Tsarfaty; G F Vande Woude
Journal:  Cancer Res       Date:  1995-05-01       Impact factor: 12.701

6.  Sporadic amplification of the MYC gene in human osteosarcomas.

Authors:  M Ladanyi; C K Park; R Lewis; S C Jhanwar; J H Healey; A G Huvos
Journal:  Diagn Mol Pathol       Date:  1993-09

7.  Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.

Authors:  P A Humphrey; X Zhu; R Zarnegar; P E Swanson; T L Ratliff; R T Vollmer; M L Day
Journal:  Am J Pathol       Date:  1995-08       Impact factor: 4.307

8.  The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit.

Authors:  R Ferracini; M F Di Renzo; K Scotlandi; N Baldini; M Olivero; P Lollini; O Cremona; M Campanacci; P M Comoglio
Journal:  Oncogene       Date:  1995-02-16       Impact factor: 9.867

9.  Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer.

Authors:  M F Di Renzo; R Poulsom; M Olivero; P M Comoglio; N R Lemoine
Journal:  Cancer Res       Date:  1995-03-01       Impact factor: 12.701

10.  Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor.

Authors:  L Naldini; L Tamagnone; E Vigna; M Sachs; G Hartmann; W Birchmeier; Y Daikuhara; H Tsubouchi; F Blasi; P M Comoglio
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

View more
  22 in total

1.  Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors.

Authors:  V Wallenius; M Hisaoka; K Helou; G Levan; N Mandahl; J M Meis-Kindblom; L G Kindblom; J O Jansson
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 2.  Epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions in the colon.

Authors:  Ferenc Sipos; Orsolya Galamb
Journal:  World J Gastroenterol       Date:  2012-02-21       Impact factor: 5.742

3.  Acute tissue injury activates satellite cells and promotes sarcoma formation via the HGF/c-MET signaling pathway.

Authors:  David Van Mater; Leonor Añó; Jordan M Blum; Micah T Webster; WeiQiao Huang; Nerissa Williams; Yan Ma; Diana M Cardona; Chen-Ming Fan; David G Kirsch
Journal:  Cancer Res       Date:  2014-12-12       Impact factor: 12.701

Review 4.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

5.  Impact of c-Met expression on angiogenesis in soft tissue sarcomas: correlation to microvessel-density.

Authors:  Cornelius Kuhnen; Thomas Muehlberger; Maria Honsel; Edina Tolnay; Hans Ulrich Steinau; Klaus-Michael Müller
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-09       Impact factor: 4.553

6.  Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid.

Authors:  Mauro Papotti; Martina Olivero; Marco Volante; Francesco Negro; Maria Prat; Paolo M. Comoglio; Maria Flavia DiRenzo
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

Review 7.  Novel targets with potential therapeutic applications in osteosarcoma.

Authors:  Chand Khanna
Journal:  Curr Oncol Rep       Date:  2008-07       Impact factor: 5.075

8.  The Current and Future Therapies for Human Osteosarcoma.

Authors:  Joseph D Lamplot; Sahitya Denduluri; Jiaqiang Qin; Ruidong Li; Xing Liu; Hongyu Zhang; Xiang Chen; Ning Wang; Abdullah Pratt; Wei Shui; Xiaoji Luo; Guoxin Nan; Zhong-Liang Deng; Jinyong Luo; Rex C Haydon; Tong-Chuan He; Hue H Luu
Journal:  Curr Cancer Ther Rev       Date:  2013-02

9.  c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells.

Authors:  E Gregory MacEwen; Jon Kutzke; Jennifer Carew; Josep Pastor; Julie A Schmidt; Rachel Tsan; Douglas H Thamm; Robert Radinsky
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

10.  MET and autism susceptibility: family and case-control studies.

Authors:  Inês Sousa; Taane G Clark; Claudio Toma; Kazuhiro Kobayashi; Maja Choma; Richard Holt; Nuala H Sykes; Janine A Lamb; Anthony J Bailey; Agatino Battaglia; Elena Maestrini; Anthony P Monaco
Journal:  Eur J Hum Genet       Date:  2008-11-12       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.